Chemomab Therapeutics Ltd.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-9.0M | $-13.9M | $-24.2M | $-27.6M | $-12.5M | $-6.0M | $-27.1M | $-13.8M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $70.0K | $53.0K | $67.0K | $58.0K | $34.0K | $24.0K | $281.0K | $66.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $623.0K | $617.0K | $1.5M | $3.2M | $2.0M | $130.0K | $1.2M | $1.9M |
| Net Cash from Operating Activities | $-11.1M | $-15.4M | $-23.6M | $-20.4M | $-12.4M | $-5.2M | $-16.5M | $-14.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $3.0K | $0 | $3.0K | $68.0K | $239.0K | $38.0K | $95.0K | $213.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $5.4M | $2.3M | $15.9M | $19.5M | $-45.2M | $-62.0K | $-95.0K | $-213.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $7.2M | $9.9M | $3.5M | $-808.0K | $61.1M | $4.8M | $26.6M | $20.6M |
| Net Change in Cash | $1.4M | $-3.2M | $-4.2M | $-1.6M | $3.5M | $-554.0K | $10.1M | $6.2M |
| Free Cash Flow | $-11.1M | $-15.4M | $-23.6M | $-20.4M | $-12.6M | $-5.3M | $-16.6M | $-14.4M |